{"title": "COVID-19, Influenza und grippe\u00e4hnliche Erkrankungen", "author": "PHC Primary; Hospital Care; L\u00e9na Dietrich; Marta Abreu De Azevedo; Sebastian Wirz; Tobias Romer; Lisa Schmid-Thurneysen; Helmut Rasch; Michael J Deml; J\u00fcrg Fr\u00f6hlich; Romeo Providoli; Thomas Ernst; Muhannad Seyam; Meliha Jusufoska; Josipa Tolic; Suzanne Suggs; Caesar Gallmann; Philipp Busche; Bernhard Wingeier; Lukas Sch\u00f6b; Anne Meynard; Oliver Hausmann; Domenica Flury; Alexandra R\u00f6llin; Helen Kovari; Charles B\u00e9guelin; Barbara Hasse; Gisela Etter; Benedikt Huber; Philip Tarr", "url": "https://phc.swisshealthweb.ch/de/article/doi/phc-d.2021.10324", "hostname": "swisshealthweb.ch", "description": "Distanzierung- und Hygienemassnahmen sind gegen Influenza und COVID-19 pr\u00e4ventiv wirksam. Bei hospitalisierten COVID-19-Patient/-innen mit Pneumonie kommt zurzeit eine Therapie mit Dexamethason mit/ohne Remdesivir in Frage. Ven\u00f6se thromboembolische Ereignisse sollen bei COVID-19 niederschwellig gesucht und vorgebeugt werden. Eine wirksame und sichere SARS-CoV-2-Impfung stellt eine enorme Herausforderung dar.", "sitename": "L\u00e9na Dietrich,Marta Abreu De Azevedo,Sebastian Wirz,Tobias Romer,Lisa Schmid-Thurneysen,Helmut Rasch,Michael J. Deml,J\u00fcrg Fr\u00f6hlich,Romeo Providoli,Thomas Ernst,Muhannad Seyam,Meliha Jusufoska,Josipa Tolic,Suzanne Suggs,Caesar Gallmann,Philipp Busche,Bernhard Wingeier,Lukas Sch\u00f6b,Anne Meynard,Oliver Hausmann,Domenica Flury,Alexandra R\u00f6llin,Helen Kovari,Charles B\u00e9guelin,Barbara Hasse,Gisela Etter,Benedikt Huber,Philip Tarr", "date": "2021-01-06", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "1 Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 2020: eabb5793.\n2 Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 2020: NEJMcp2009249.\n3 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020: NEJMcp2009575.\n4 Paules C, Subbarao K. Influenza. Lancet 2017; 390: 697\u2013708.\n5 Labella AM, Merel SE. Influenza. Med Clin North Am. 2013;97:621\u201345\u2013x.\n6 Ghebrehewet S, MacPherson P, Ho A. Influenza. BMJ. 2016;355:i6258.\n7 Gon\u00e7alves AR, Kaiser L. Was steckt hinter der Grippe? Swiss Medical Forum. 2019 19:181\u20136.\n9 Gschwend E, Trageser J, Stokar INFRAS von T. Erfassung der Datenlage zur Absch\u00e4tzung der Krankheitslast der saisonalen Grippe in der Schweiz, Bundesamt f\u00fcr Gesundheit BAG, Abteilung \u00fcbertragbare Krankheiten. 2018; published online Dec 10.\n[https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/grips/executive-summary-erfassung-datenlage-saisonale-grippe.pdf.download.pdf/executive-suummary-erfassung-datenlage-saisonale-grippe-de.pdf](https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/grips/executive-summary-erfassung-datenlage)\n(accessed June 9, 2020).\n10 Brunner I, Schmedders K, Wolfensberger A, Schreiber PW, Kuster SP. The economic and public health impact of influenza vaccinations: contributions of Swiss pharmacies in the 2016/17 and 2017/18 influenza seasons and implications for vaccination policy. Swiss Med Wkly. 2019;149:w20161.\n11 Bundesamt f\u00fcr Gesundheit. Bericht zur Grippesaison 2018/19. BAG Bulletin 29 2019: 9\u201321.\n[https://www.infovac.ch/docs/public/influenza/bericht-zur-grippesaison-2018-19-.pdf](https://www.infovac.ch/docs/public/influenza/bericht-zur-grippesaison-2018-19-.pdf)\n12 Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48:2940\u20137.\n13 Menni C, Valdes AM, Freidin MB, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med 2020; 368: m1202\u20134.\n14 Hopkins C, Surda P, Kumar N. Presentation of new onset anosmia during the COVID-19 pandemic. Rhinology 2020; published online April 11.\n[DOI:10.4193/Rhin20.116](DOI:10.4193/Rhin20.116)\n.\n15 Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome? Rhinology 2020; published online April 2. DOI:10.4193/Rhin20.114.\n16 Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia: Common Findings in COVID-19 Patients. Laryngoscope. 2020;xiv:26.\n17 Br\u00e4merson A, Johansson L, Ek L, Nordin S, Bende M. Prevalence of olfactory dysfunction: the sk\u00f6vde population-based study. Laryngoscope. 2004;114:733\u20137.\n18 Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. Euro Surveill. 2020;25:267.\n19 Souty C, Masse S, Valette M, et al. Baseline characteristics and clinical symptoms related to respiratory viruses identified among patients presenting with influenza-like illness in primary care. Clin Microbiol Infect. 2019;25:1147\u201353.\n20 Monto AS, DeJonge P, Callear AP, et al. Coronavirus occurrence and transmission over 8 years in the HIVE cohort of households in Michigan. J Infect Dis 2020; published online April 4.\n[DOI:10.1093/infdis/jiaa161](DOI:10.1093/infdis/jiaa161)\n.\n21 Heikkinen T, J\u00e4rvinen A. The common cold. The Lancet. 2003;361:51\u20139.\n22 Minodier L, Charrel RN, Ceccaldi P-E, et al. Prevalence of gastrointestinal symptoms in patients with influenza, clinical significance, and pathophysiology of human influenza viruses in faecal samples: what do we know? Virol J. 2015;12:215\u20139.\n23 Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.\n24 Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. American Journal of Epidemiology. 2008;167:775\u201385.\n25 Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respir Med. 2014;2:445\u201354.\n26 Mohammad S, Korn K, Schellhaas B, Neurath MF, Goertz RS. Clinical Characteristics of Influenza in Season 2017/2018 in a German Emergency Department: A Retrospective Analysis. Microbiol Insights. 2019;12:1178636119890302.\n27 Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020;382:2081\u201390.\n28 Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles\u2019 Heel of Current Strategies to Control Covid-19. N Engl J Med. 2020;382:2158\u201360.\n29 Day M. Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ. 2020;369:m1375.\n30 Low N. Rapid Response: Re: Covid-19: four fifths of cases are asymptomatic, China figures indicate. BMJ 2020; published online April 3.\n31 O\u2019Reilly F, Dolan GP, Nguyen-Van-Tam J, Noone P. Practical prevention of nosocomial influenza transmission, \u2018a hierarchical control\u2019 issue. Occup Med (Lond). 2015;65:696\u2013700.\n32 Patrozou E, Mermel LA. Does influenza transmission occur from asymptomatic infection or prior to symptom onset? Public Health Rep. 2009;124:193\u20136.\n33 Ip DKM, Lau LLH, Leung NHL, et al. Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community. Clin Infect Dis. 2017;64:736\u201342.\n34 Lau LLH, Nishiura H, Kelly H, Ip DKM, Leung GM, Cowling BJ. Household transmission of 2009 pandemic influenza A (H1N1): a systematic review and meta-analysis. Epidemiology. 2012;23:531\u201342.\n35 Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003; 37: 1094\u2013101.\n36 Zimmerman RK. Ethical analyses of institutional measures to increase health care worker influenza vaccination rates. Vaccine. 2013;31:6172\u20136.\n37 Jhung MA, D\u2019Mello T, P\u00e9rez A, et al. Hospital-onset influenza hospitalizations--United States, 2010-2011. Am J Infect Control 2014; 42: 7\u201311.\n38 Buckrell S, Coleman BL, McNeil SA, et al. Sources of viral respiratory infections in Canadian acute care hospital healthcare personnel. J Hosp Infect. 2020;104:513\u201321.\n39 Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). 2020; published online Jan.\n[https://www.ncbi.nlm.nih.gov/books/NBK554776/](https://www.ncbi.nlm.nih.gov/books/NBK554776/)\n40 Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26:506\u201310.\n41 He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26: 672\u20135.\n42 Zhu L, Wang J, Huang R, et al. Clinical characteristics of a case series of children with coronavirus disease 2019. Pediatr Pulmonol. 2020;55:1430\u20132.\n43 Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020;382:1177\u20139.\n44 Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. 2020;395:497.\n45 Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. (2020) Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med 17(9): e1003346.\n[https://doi.org/10.1371/journal.pmed.1003346](https://doi.org/10.1371/journal.pmed.1003346)\n46 Oh YN, Kim S, Choi YB, Woo SI, Hahn Y-S, Lee JK. Clinical similarities between influenza A and B in children: a single-center study, 2017/18 season, Korea. BMC Pediatr 2019; 19: 472\u20138.\n47 Reed C, Chaves SS, Daily Kirley P, et al. Estimating influenza disease burden from population-based surveillance data in the United States. PLoS ONE 2015; 10: e0118369.\n48 Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54: 1427\u201336.\n49 Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362:1733\u201345.\n50 Walker TA, Waite B, Thompson MG, et al. Risk of Severe Influenza Among Adults With Chronic Medical Conditions. J Infect Dis. 2020;221:183\u201390.\n51 Schanzer DL, Langley JM, Tam TWS. Co-morbidities associated with influenza-attributed mortality, 1994\u20132000, Canada. Vaccine. 2008;26:4697\u2013703.\n52 Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. The Lancet Infectious Diseases. 2009;9:601\u201310.\n54 Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395:809\u201315.\n55 Qiao J. What are the risks of COVID-19 infection in pregnant women? Lancet. 2020;395:760\u20132.\n56 Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. JAMA. 2020;323:1848\u20139.\n57 Rauh AL, Linder JA. Covid-19 care before, during, and beyond the hospital. BMJ. 2020;369:m2035.\n58 Schweizerischen Gesellschaft f\u00fcr Pneumologie. Erl\u00e4uterung und Stellungsnahme der Schweizerischen Gesellschaft f\u00fcr Pneumologie betreffend dem Verst\u00e4ndnis Chronischer Lungenkrankheiten als Risiko f\u00fcr einen schwerwiegenden Verlauf bei Infektion mit SARS CoViD19. 2020; published online March 17.\n[http://www.pneumo.ch/files/pneumo/pdf/news/2020/Empfehlungen%20und%20Stellungnahme%20der%20SGP%20DE_27420.pdf](http://www.pneumo.ch/files/pneumo/pdf/news/2020/Empfehlungen%20und%20Stellungnahme%20der%20SGP%20DE_)\n(accessed May 17, 2020).\n59 Schweizerischen Hypertonie-Gesellschaft. Stelllungsnahme der Schweizerischen Hypertonie Gesellschaft (SHG) zur arteriellen Hypertonie und der COVID-19 Infektion. 2020; published online March 19.\n[http://www.swisshypertension.ch/DOCS_PUBLIC/Stellungnahme_COVID_19_D.pdf](http://www.swisshypertension.ch/DOCS_PUBLIC/Stellungnahme_COVID_19_D.pdf)\n(accessed May 17, 2020).\n60 Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; : NEJMoa2006923.\n61 Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; : NEJMoa2008975.\n62 Jarcho JA, Ingelfinger JR, Hamel MB, D\u2019Agostino RB, Harrington DP. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19. N Engl J Med 2020; : NEJMe2012924.\n63 Schweizerische Gesellschaft f\u00fcr Endokrinologie und Diabetologie. Informationen zu COVID-19 Informationen betreffend COVID-19 und Adipositas. 2020; published online April 20.\n[https://www.sgedssed.ch/diabetologie/covid-19](https://www.sgedssed.ch/diabetologie/covid-19)\n64 Simonnet A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) 2020; published online April 9.\n[DOI:10.1002/oby.22831](DOI:10.1002/oby.22831)\n.\n65 Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020;3:29.\n66 Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerging Infect Dis. 2008;14:95\u2013100.\n67 Swamy GK, Heine RP. Vaccinations for pregnant women. Obstetrics & Gynecology 2015;125:212\u201326.\n68 Omer SB. Maternal Immunization. N Engl J Med 2017; 376: 1256\u201367.\n69 Fell DB, Platt RW, Lanes A, et al. Fetal death and preterm birth associated with maternal influenza vaccination: systematic review. BJOG 2015;122:17\u201326.\n70 Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. American Journal of Epidemiology. 1982;116:212\u201327.\n71 Glezen WP, Keitel WA, Taber LH, Piedra PA, Clover RD, Couch RB. Age distribution of patients with medically-attended illnesses caused by sequential variants of influenza A/H1N1: comparison to age-specific infection rates, 1978-1989. American Journal of Epidemiology. 1991;133:296\u2013304.\n72 JORDAN WS, DENNY FW, BADGER GF, et al. A study of illness in a group of Cleveland families. XVII. The occurrence of Asian influenza. Am J Hyg. 1958;68:190\u2013212.\n73 Heikkinen T, Silvennoinen H, Peltola V, et al. Burden of influenza in children in the community. Journal of Infectious Diseases. 2004;190:1369\u201373.\n74 Hsiao A, Buck PO, Yee A, et al. Retrospective study of the use of an influenza disease two-tiered classification system to characterize clinical severity in US children. Hum Vaccin Immunother. 2020;58:1\u20139.\n75 Heikkinen T, Silvennoinen H, Heinonen S, Vuorinen T. Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children. Eur J Clin Microbiol Infect Dis 2016; 35: 1107\u201313.\n76 Winther B, Block SL, Reisinger K, Dutkowski R. Impact of oseltamivir treatment on the incidence and course of acute otitis media in children with influenza. Int J Pediatr Otorhinolaryngol 2010; 74: 684\u20138.\n77 Parri N, Lenge M, Buonsenso D, Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in Pediatric Emergency Departments in Italy. N Engl J Med 2020; : NEJMc2007617.\n78 Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases 2020; published online April 27.\n[DOI:10.1016/S1473-3099(20)30287-5](DOI:10.1016/S1473-3099(20)30287-5)\n.\n79 Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020; published online June 8.\n[DOI:10.1001/jama.2020.10369](DOI:10.1001/jama.2020.10369)\n.\n80 McCrindle BW, Manlhiot C. SARS-CoV-2-Related Inflammatory Multisystem Syndrome in Children: Different or Shared Etiology and Pathophysiology as Kawasaki Disease? JAMA 2020; published online June 8.\n[DOI:10.1001/jama.2020.10370](DOI:10.1001/jama.2020.10370)\n.\n81 Williams CJ, Schweiger B, Diner G, et al. Seasonal influenza risk in hospital healthcare workers is more strongly associated with household than occupational exposures: results from a prospective cohort study in Berlin, Germany, 2006/07. BMC Infect Dis. 2010;10:8\u201311.\n82 Viboud C, Bo\u00eblle P-Y, Cauchemez S, et al. Risk factors of influenza transmission in households. Br J Gen Pract 2004; 54: 684\u20139.\n83 Musher DM. How contagious are common respiratory tract infections? N Engl J Med. 2003;348:1256\u201366.\n84 Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19: An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children. The Pediatric Infectious Disease Journal 2020; 39: 355\u201368.\n85 Swiss National COVID-19 Science Task Force. The role of children (0-18 years of age) in the transmission of SARS-CoV-2: rapid review. 2020; published online May 10.\n[https://ncs-tf.ch/de/policy-briefs](https://ncs-tf.ch/de/policy-briefs)\n(accessed June 14, 2020).\n86 Bundesamt f\u00fcr Gesundheit. COVID-19 Grundprinzipien Wiederaufnahme des Pr\u00e4senzunterrichts an obligatorischen Schulen als Grundlage f\u00fcr die Ausarbeitung der Schutzkonzepte der Schulen unter Ber\u00fccksichtigung der Betreuungseinrichtungen und Musikschulen. 2020; published online May 1.\n[https://www.ag.ch/media/kanton_aargau/themen_1/coronavirus_1/merkblaetter/20200505_Grundprinzipien_Schutzkonzept_obligatorische_Schulen_Betreuungseinrichtungen_Musikschulen.pdf](https://www.ag.ch/media/kanton_aargau/themen_1/coronavirus_1/merkblaetter/20200505_Grundprinzipien_S)\n(accessed May 17, 2020).\n87 Viner RM, Russell SJ, Croker H, et al. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. Lancet Child Adolesc Health. 2020;4:397\u2013404.\n88 Mallapaty S. How do children spread the coronavirus? The science still isn\u2019t clear. Nature. 2020;581:127\u20138.\n89 Jones T, M\u00fchlemann B, Veith T. An analysis of SARS-CoV2 viral load by patient age. 2020; published online April 30.\n[https://www.drperlmutter.com/wp-content/uploads/2020/05/analysis-of-SARS-CoV-2-viral-load-by-patient-age.pdf](https://www.drperlmutter.com/wp-content/uploads/2020/05/analysis-of-SARS-CoV-2-viral-load-by-patient)\n(accessed May 17, 2020).\n90 Mandavilli A. New Studies Add to Evidence that Children May Transmit the Coronavirus. The New York Times Company. 2020; published online May 5.\n[https://nyti.ms/2SDdFiM](https://nyti.ms/2SDdFiM)\n91 Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2018; 2: CD001269.\n92 Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2018; 2: CD004876.\n93 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE). John Hopkins. 2020.\n[https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6](https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6)\n(accessed May 31, 2020).\n94 Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020; 172: 577\u201382.\n95 Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerging Infect Dis. 2020;26:1470\u20137.\n96 Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; : NEJMoa2002032.\n97 Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020; published online March 27.\n[DOI:10.1001/jamacardio.2020.1017](DOI:10.1001/jamacardio.2020.1017)\n.\n98 Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med 2020:NEJMoa2004500.\n99 ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. American Medical Association, 2012: 2526\u201333.\n100 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094\u20139.\n101 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054\u201362.\n102 Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18:1324\u20139.\n103 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18: 844\u20137.\n104 Breakey N, Escher R. D-dimer and mortality in COVID-19: a self-fulfilling prophecy or a pathophysiological clue? Swiss Med Wkly 2020; 150: w20293.\n105 Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020; published online April 10.\n[DOI:10.1001/jamaneurol.2020.1127](DOI:10.1001/jamaneurol.2020.1127)\n.\n106 Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S. Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. JAMA Neurol 2020; published online May 29.\n[DOI:10.1001/jamaneurol.2020.2065](DOI:10.1001/jamaneurol.2020.2065)\n.\n107 Fauci AS, Lane HC, Redfield RR. Covid-19 \u2013 Navigating the Uncharted. N Engl J Med 2020; 382: 1268\u20139.\n108 Lindb\u00e4ck S, Hellgren U, Julander I, Hansson LO. The value of C-reactive protein as a marker of bacterial infection in patients with septicaemia/endocarditis and influenza. Scand J Infect Dis 1989; 21: 543\u20139.\n109 Haran JP, Suner S, Gardiner F. Correlation of C-reactive protein to severity of symptoms in acute influenza A infection. J Emerg Trauma Shock 2012; 5: 149\u201352.\n110 Vasileva D, Badawi A. C-reactive protein as a biomarker of severe H1N1 influenza. Inflamm Res 2019; 68: 39\u201346.\n111 van Vugt SF, Broekhuizen BDL, Lammens C, et al. Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ 2013; 346: f2450\u20130.\n112 Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; published online April 22.\n[DOI:10.1001/jama.2020.6775](DOI:10.1001/jama.2020.6775)\n.\n113 Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with COVID-19. Clin Infect Dis 2020; published online May 23.\n[DOI:10.1093/cid/ciaa641](DOI:10.1093/cid/ciaa641)\n.\n114 Bhargava A, Fukushima EA, Levine M, et al. Predictors for Severe COVID-19 Infection. Clin Infect Dis 2020; published online May 30.\n[DOI:10.1093/cid/ciaa674](DOI:10.1093/cid/ciaa674)\n.\n115 Spencer S, Thompson MG, Flannery B, Fry A. Comparison of Respiratory Specimen Collection Methods for Detection of Influenza Virus Infection by Reverse Transcription-PCR: a Literature Review. J Clin Microbiol 2019; 57: 560.\n116 Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; published online March 11. DOI:10.1001/jama.2020.3786.\n117 Center for Disease Control and Prevention. Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19. 2020; published online May 3.\n[https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html](https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html)\n(accessed June 14, 2020).\n118 W\u00f6lfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; published online April 1.\n[DOI:10.1038/s41586-020-2196-x](DOI:10.1038/s41586-020-2196-x)\n.\n119 Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis 2020; published online May 22.\n[DOI:10.1093/cid/ciaa638](DOI:10.1093/cid/ciaa638)\n.\n120 Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA 2013; 309: 275\u201382.\n121 Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395: 514\u201323.\n122 Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020; published online March 12.\n[DOI:10.1093/cid/ciaa247](DOI:10.1093/cid/ciaa247)\n.\n123 Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients. AJR Am J Roentgenol 2020; : 1\u20137.\n124 Sun Z. Diagnostic Value of Chest CT in Coronavirus Disease 2019 (COVID-19). Curr Med Imaging 2020; 16: 274\u20135.\n125 Wang Y, Dong C, Hu Y, et al. Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study. Radiology 2020; : 200843.\n126 Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. Radiology 2020; 295: 200463.\n127 Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology 2020; : 200823.\n128 Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371: 1619\u201328.\n129 Metersky ML, Masterton RG, Lode H, File TM, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis 2012; 16: e321\u201331.\n130 Lamichhane PP, Samarasinghe AE. The Role of Innate Leukocytes during Influenza Virus Infection. J Immunol Res 2019; 2019: 8028725\u201317.\n131 Whicher JT, Chambers RE, Higginson J, Nashef L, Higgins PG. Acute phase response of serum amyloid A protein and C reactive protein to the common cold and influenza. J Clin Pathol 1985; 38: 312\u20136.\n132 Edelbauer M, W\u00fcrzner R, Jahn B, Zimmerhackl LB. C-reactive protein and leukocytes do not reliably indicate severity of influenza a infection in childhood. Clin Pediatr (Phila) 2006; 45: 531\u20136.\n133 Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections--full version. Clin. Microbiol. Infect. 2011; 17 Suppl 6: E1\u201359.\n134 Woloshin S, Patel N, Kesselheim AS. False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med 2020; : NEJMp2015897.\n135 Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19 Antibody Tests - At What Cost? N Engl J Med 2020; : NEJMp2017739.\n136 Ng K, Faulkner N, Cornish G, et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. bioRxiv 2020; : 2020.05.14.095414.\n137 Jacobs JJL. Neutralizing antibodies mediate virus-immune pathology of COVID-19. Med Hypotheses 2020; 143: 109884.\n138 European Network For Helath Technology Assessment, Ballini L, Djuric O, Venturelli F. Rapid collaborative review on the current role of antibodytests for novel coronvirus SARS-COV-2 in the mangement of the pandemic - Project ID: RCR OT 01. 2020; published online June 22.\n[https://www.iqwig.de/download/RCR_OT_01-_Antibody-tests-for-SARS-CoV-2_23-06-2020.pdf](https://www.iqwig.de/download/RCR_OT_01-_Antibody-tests-for-SARS-CoV-2_23-06-2020.pdf)\n(accessed July 5, 2020).\n139 Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. Pediatr Allergy Immunol 2020; 2: e200110.\n140 Ellinghaus D, Degenhardt F, Bujanda L, et al. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv 2020: 2020.05.31.20114991.\n141 Owen WF, Carmona R, Pomeroy C. Failing Another National Stress Test on Health Disparities. JAMA. 2020;323:1905\u20136.\n142 Yancy CW. COVID-19 and African Americans. JAMA. 2020;323:1891\u20132.\n143 Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med 2020: NEJMsa2011686.\n144 Swiss National COVID-19 Science Task Force. Strategie, um die SARS-CoV-2-Epidemie zu kontrollieren. 2020; published online May 26.\n[https://ncs-tf.ch/de/policy-briefs?layout=default](https://ncs-tf.ch/de/policy-briefs?layout=default)\n(accessed June 14, 2020).\n145 Germann M, Hilfiker A, Huber BM. Immunstimulation zur Pr\u00e4vention und Therapie von akuten Luftwegsinfektionen. Primary and hospital care; 19: 345\u20139.\n146 Cohen S, Doyle WJ, Alper CM, Janicki-Deverts D, Turner RB. Sleep habits and susceptibility to the common cold. Arch Intern Med 2009; 169: 62\u20137.\n147 Satomura K, Kitamura T, Kawamura T, et al. Prevention of upper respiratory tract infections by gargling: a randomized trial. Am J Prev Med 2005; 29: 302\u20137.\n148 Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials. Lancet Diabetes Endocrinol 2017; 5: 986\u20131004.\n149 Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 2017; 356: i6583.\n150 Karsch-V\u00f6lk M, Barrett B, Linde K. Echinacea for preventing and treating the common cold. JAMA 2015; 313: 618\u20139.\n151 Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. The Lancet Infectious Diseases 2007; 7: 473\u201380.\n152 Jawad M, Schoop R, Suter A, Klein P, Eccles R. Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med 2012; 2012: 841315\u20137.\n153 Weber W, Taylor JA, Stoep AV, Weiss NS, Standish LJ, Calabrese C. Echinacea purpurea for prevention of upper respiratory tract infections in children. J Altern Complement Med 2005; 11: 1021\u20136.\n154 Swissnoso. Interims Vorsorgemassnahmen in Spit\u00e4lern f\u00fcr einenhospitalisierten Patienten mit begr\u00fcndetem Verdacht oder mit einer best\u00e4tigten COVID-19 Infektion. 2020; published online May 5.\n[https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/5_Forschung_und_Entwicklung/6_Aktuelle_Erreignisse/200505_Vorsorgemassnahmen_COVID-19_Spital_V7.2_DE.pdf](https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/5_Forschung_und_Entwicklung/6_Aktuelle_Erreig)\n(accessed May 21, 2020).\n155 Cheng VCC, Tai JWM, Wong LMW, et al. Prevention of nosocomial transmission of swine-origin pandemic influenza virus A/H1N1 by infection control bundle. J Hosp Infect 2010; 74: 271\u20137.\n156 Blanco N, Eisenberg MC, Stillwell T, Foxman B. What Transmission Precautions Best Control Influenza Spread in a Hospital? American Journal of Epidemiology 2016; 183: 1045\u201354.\n157 Grayson ML, Melvani S, Druce J, et al. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis 2009; 48: 285\u201391.\n158 Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, Centre for the Mathematical Modelling of Infectious Diseases COVID-19 working group. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health 2020; published online June 2.\n[DOI:10.1016/S2468-2667(20)30133-X](DOI:10.1016/S2468-2667(20)30133-X)\n.\n159 Aiello AE, Coulborn RM, Perez V, Larson EL. Effect of hand hygiene on infectious disease risk in the community setting: a meta-analysis. Am J Public Health 2008; 98: 1372\u201381.\n160 Cowling BJ, Zhou Y, Ip DKM, Leung GM, Aiello AE. Face masks to prevent transmission of influenza virus: a systematic review. Epidemiol Infect 2010; 138: 449\u201356.\n161 Aiello AE, Perez V, Coulborn RM, Davis BM, Uddin M, Monto AS. Facemasks, hand hygiene, and influenza among young adults: a randomized intervention trial. PLoS ONE 2012; 7: e29744.\n162 Ferguson N, Laydon D, Nedjati-Gilani G. Imperial College COVID-19 Response Team. Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. 2020; published online March 16.\n[https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-16-COVID19-Report-9.pdf](https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-16-COVID19-Report-9.pdf)\n(accessed June 14, 2020).\n163 Koo JR, Cook AR, Park M, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. The Lancet Infectious Diseases 2020; published online March 23. DOI:10.1016/S1473-3099(20)30162-6.\n164 Swiss National COVID-19 Science Task Force. Role of Face masks as part of non-pharmaceutical interventions against coronavirus disease. 2020; published online April 20.\n[https://ncs-tf.ch/de/policy-briefs?layout=default](https://ncs-tf.ch/de/policy-briefs?layout=default)\n(accessed June 14, 2020).\n165 Verbindung der Schweizer \u00c4rztinnen und \u00c4rzte. COVID-19: Schutzkonzept der FMH zum Betrieb von Arztpraxen. FMH. 2020; published online April 22.\n[https://www.sgaim.ch/fileadmin/user_upload/BilderHighres/Seiteninhalte/200423_COVID-19_Schutzkonzept_FMH.pdf](https://www.sgaim.ch/fileadmin/user_upload/BilderHighres/Seiteninhalte/200423_COVID-19_Schutzkonzept)\n(accessed May 18, 2020).\n166 Offeddu V, Yung CF, Low MSF, Tam CC. Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. Clin Infect Dis 2017; 65: 1934\u201342.\n167 Chan AT, Brownstein JS. Putting the Public Back in Public Health \u2013 Surveying Symptoms of Covid-19. N Engl J Med 2020; : NEJMp2016259.\n168 Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. The Lancet Infectious Diseases 2014; 14: 109\u201318.\n169 Tsang TK, Lau LLH, Cauchemez S, Cowling BJ. Household Transmission of Influenza Virus. Trends Microbiol 2016; 24: 123\u201333.\n170 Tsang TK, Cowling BJ, Fang VJ, Chan K-H. Influenza A Virus Shedding and Infectivity in Households. Journal of Infectious Diseases 2015; 212: 1420\u20138.\n171 Papenburg J, Baz M, Hamelin M-\u00c8, et al. Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory\u2010confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis 2010; 51: 1033\u201341.\n172 Cheung DH, Tsang TK, Fang VJ, et al. Association of Oseltamivir Treatment With Virus Shedding, Illness, and Household Transmission of Influenza Viruses. J Infect Dis 2015; 212: 391\u20136.\n173 Jackson ML, France AM, Hancock K, et al. Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave-New York City, April-May 2009. Clin Infect Dis 2011; 53: 455\u201362.\n174 Heininger U, Seward JF. Varicella. Lancet 2006; 368: 1365\u201376.\n175 Tarr PE, Gallmann C, Heininger U. Masern in der Schweiz. Erkennung und Impfberatung. Schweiz Med Forum; 8: 868\u201372.\n176 Kuster SP, Shah PS, Coleman BL, et al. Incidence of influenza in healthy adults and healthcare workers: a systematic review and meta-analysis. PLoS ONE 2011; 6: e26239.\n177 Balmer D. Corona in den Krankenh\u00e4usern - 2100 Covid-F\u00e4lle beim Spitalpersonal. Tages-Anzeiger. 2020; published online May 31.\n178 Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in human beings. The Lancet Infectious Diseases 2007; 7: 257\u201365.\n179 Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007;28:1071\u20136.\n180 van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564\u20137.\n181 Larson EL, Lin SX, Gomez-Pichardo C, Della-Latta P. Effect of antibacterial home cleaning and handwashing products on infectious disease symptoms: a randomized, double-blind trial. Ann Intern Med 2004; 140: 321\u20139.\n182 Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2011; 141: CD006207.\n184 Stadnytskyi V, Bax CE, Bax A, Anfinrud P. The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. Proc Natl Acad Sci USA 2020; 12: 202006874.\n185 Tang JW, Gao CX, Cowling BJ, et al. Absence of detectable influenza RNA transmitted via aerosol during various human respiratory activities-experiments from Singapore and Hong Kong. PLoS ONE 2014; 9: e107338.\n186 K\u00fcbler S. Wenig schreien, nicht k\u00fcssen. Tages-Anzeiger. 2020; published online May 23.\n187 Rubens JH, Karakousis PC, Jain SK. Stability and Viability of SARS-CoV-2. N Engl J Med 2020; 382: 1962\u20133.\n188 Ng K, Poon BH, Kiat Puar TH, et al. COVID-19 and the Risk to Health Care Workers: A Case Report. Ann Intern Med 2020; : L20\u20130175.\n189 Bundesamt f\u00fcr Gesundheit. Neues Coronavirus: Schutzmassnahmen f\u00fcr Gesundheitsfachpersonen und besonders gef\u00e4hrdete Personen. 2020; published online April 22.\n[https://nvs.swiss/Dokumente/Rubrik-Aktuell/2020/Corona-Virus/Schutzmassnahmen-BAG.pdf](https://nvs.swiss/Dokumente/Rubrik-Aktuell/2020/Corona-Virus/Schutzmassnahmen-BAG.pdf)\n(accessed June 14, 2020).\n190 Loeb M, Dafoe N, Mahony J, et al. Surgical mask vs N95 respirator for preventing influenza among health care workers: a randomized trial. JAMA 2009; 302: 1865\u201371.\n191 Radonovich LJ, Simberkoff MS, Bessesen MT, et al. N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. JAMA 2019; 322: 824\u201333.\n192 Johnson DF, Druce JD, Birch C, Grayson ML. A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection. Clin Infect Dis 2009; 49: 275\u20137.\n193 Seto W-H, Cowling BJ, Lam H-S, Ching PTY, To M-L, Pittet D. Clinical and nonclinical health care workers faced a similar risk of acquiring 2009 pandemic H1N1 infection. Clin Infect Dis 2011; 53: 280\u20133.\n194 Stupica D, Lusa L, Petrovec M, et al. Respiratory viruses in patients and employees in an intensive care unit. Infection 2012; 40: 381\u20138.\n195 Kuster SP, Coleman BL, Raboud J, et al. Risk factors for influenza among health care workers during 2009 pandemic, Toronto, Ontario, Canada. Emerging Infect Dis 2013; 19: 606\u201315.\n196 Chu DK, Akl EA, Duda S, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet 2020; published online June 1.\n[DOI:10.1016/S0140-6736(20)31142-9](DOI:10.1016/S0140-6736(20)31142-9)\n.\n197 Br\u00f6nnimann C. Diese Dokumente zeigen, wie der Bund die Pandemie untersch\u00e4tzt hat. Sonntagszeitung Tagesanzeiger. 2020; published online June 13.\n198 Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L. Face masks for the public during the covid-19 crisis. BMJ 2020; 369: m1435.\n199 Leung NHL, Chu DKW, Shiu EYC, et al. Author Correction: Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med 2020:1\u20131.\n200 Howard RA, Lathrop GW, Powell N. Sterile field contamination from powered air-purifying respirators (PAPRs) versus contamination from surgical masks. Am J Infect Control 2020;48:153\u20136.\n201 Cheng VC-C, Wong S-C, Chuang VW-M, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. J Infect 2020; published online April 23.\n[DOI:10.1016/j.jinf.2020.04.024](DOI:10.1016/j.jinf.2020.04.024)\n.\n202 Bundesamt f\u00fcr Gesundheit. COVID-19-Epidemie, Empfehlungen zur Anwendung von Schutzmaterial. 2020; published online March 14.\n[https://www.spitexzh.ch/files/G3AVADM/empfehlungen_anwendung_schutzmaterial_2.pdf](https://www.spitexzh.ch/files/G3AVADM/empfehlungen_anwendung_schutzmaterial_2.pdf)\n(accessed June 14, 2020).\n203 Bundesamt f\u00fcr Gesundheit. Tragen von Hygienemasken im \u00f6ffentlichen Raum. Fragen und Antworten. 2020; published online April 22.\n[https://www.newsd.admin.ch/newsd/message/attachments/61029.pdf](https://www.newsd.admin.ch/newsd/message/attachments/61029.pdf)\n(accessed May 31, 2020).\n204 Coronavirus Disease 2019 (COVID-19). Use of Cloth Face Coverings to Help Slow the Spread of COVID-19 2020; published online June 28.\n[https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html](https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html)\n. (accessed June 30, 2020).\n205 MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open 2015; 5: e006577\u20137.\n206 MacIntyre CR, Seale H, Dung TC, et al. COVID-19, shortages of masks and the use of cloth masks as a last resort. BMJ Open 2020.\n207 Duckworth A, Ungar L, Emanuel EJ. There Are 3 Things We Have to Do to Get People Wearing Masks. The New York Times Company. 2020; published online May 27.\n208 Zanasi A, Mazzolini M, Tursi F, Morselli-Labate AM, Paccapelo A, Lecchi M. Homeopathic medicine for acute cough in upper respiratory tract infections and acute bronchitis: a randomized, double-blind, placebo-controlled trial. Pulm Pharmacol Ther 2014; 27: 102\u20138.\n209 Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ. Oseltamivir: the real world data. BMJ 2014; 348: g2371\u20131.\n210 Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266.\n211 Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014;348:g2545\u20135.\n212 Cochrane Neuraminidase Inhibitors Review Team. Does oseltamivir really reduce complications of influenza? Clin Infect Dis 2011; 53: 1302\u20133\u2013authorreply1303\u20134.\n213 Godlee F. Open letter to Roche about oseltamivir trial data. BMJ 2012; 345: e7305\u20135.\n214 Loder E, Tovey D, Godlee F. The Tamiflu trials. BMJ 2014; 348: g2630\u20130.\n215 Krumholz HM. Neuraminidase inhibitors for influenza. BMJ 2014; 348: g2548.\n216 Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385: 1729\u201337.\n217 Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395\u2013404.\n218 Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55: 1198\u2013204.\n219 Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020; 395: 42\u201352.\n220 Katzen J, Kohn R, Houk JL, Ison MG. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes. Clin Infect Dis 2019; 69: 52\u20138.\n221 de Jong MD. Facilitating Early Treatment of Influenza in Hospitals: Empiric Antivirals or Empiric Diagnostics? Clin Infect Dis 2019; 69: 59\u201360.\n222 Lee N, Hui DSC, Zuo Z, et al. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Clin Infect Dis 2013; 57: 1511\u20139.\n223 South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346: f3039\u20139.\n224 Reisinger K, Greene G, Aultman R, Sander B, Gyldmark M. Effect of influenza treatment with oseltamivir on health outcome and costs in otherwise healthy children. Clin Drug Investig 2004; 24: 395\u2013407.\n225 Malosh RE, Martin ET, Heikkinen T, Brooks WA, Whitley RJ, Monto AS. Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials. Clin Infect Dis 2018; 66: 1492\u2013500.\n226 Jones M, Tett SE, Del Mar C. Psychiatric adverse events in oseltamivir prophylaxis trials: Novel comparative analysis using data obtained from clinical study reports. Pharmacoepidemiol Drug Saf 2018; 27: 1217\u201322.\n227 Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31: 1097\u2013114.\n228 Ueda N, Umetsu R, Abe J, et al. Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biol Pharm Bull 2015; 38: 1638\u201344.\n229 Bassetti M, Castaldo N, Carnelutti A. Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives. Expert Opin Pharmacother 2019; 20: 1711\u20138.\n230 Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68: e1\u2013e47.\n231 Pleschka S, Stein M, Schoop R, Hudson JB. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J 2009; 6: 197\u20139.\n232 Rau\u0161 K, Pleschka S, Klein P, Schoop R, Fisher P. Effect of an Echinacea-Based Hot Drink Versus Oseltamivir in Influenza Treatment: A Randomized, Double-Blind, Double-Dummy, Multicenter, Noninferiority Clinical Trial. Curr Ther Res Clin Exp 2015; 77: 66\u201372.\n233 Wang Y, Fan G, Salam A, et al. Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection. J Infect Dis 2020; 221: 1688\u201398.\n234 McCreary EK, Pogue JM. Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. Open Forum Infect Dis 2020; 7: ofaa105.\n235 Cohen MS, Corey L. Combination prevention for COVID-19. Science 2020; 368: 551\u20131.\n236 Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; : NEJMoa2016638.\n237 Guidelines of the Swiss Society for Infectious Diseases. SARS-CoV-2 /COVID-19 - Antiviral and immunomodulatory treatment considerations (continually updated). 2020.\n[https://ssi.guidelines.ch/guideline/3352](https://ssi.guidelines.ch/guideline/3352)\n(accessed May 18, 2020).\n238 Li Z, Wang X, Cao D, Sun R, Li C, Li G. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther 2020; 14: 73\u20136.\n239 Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; : NEJMoa2007016.\n240 Wang Y, Zhang D, Du G. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2020; published online April 29.\n241 Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med 2020: NEJMoa2007764.\n242 European Medicines Agency. First COVID-19 treatment recommended for EU authorisation. 2020; published online June 25.\n[https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authorisation_en.pdf](https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authori)\n(accessed July 5, 2020).\n243 Lawless J, Olsen J, Johnson L. The New York Times - Health Experts Slam US Deal for Large Supply of Virus Drug. 2020; published online July 1.\n[https://www.nytimes.com/aponline/2020/07/01/world/europe/bc-eu-virus-outbreak-us-hoarding.html](https://www.nytimes.com/aponline/2020/07/01/world/europe/bc-eu-virus-outbreak-us-hoarding.html)\n(accessed July 5, 2020).\n244 Coomes EA, Haghbayan H. Favipiravir, an antiviral for COVID-19? J Antimicrob Chemother 2020; 75: 2013\u20134.\n245 Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; : NEJMoa2001282.\n246 Villar J, Ferrando C, Mart\u00ednez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8: 267\u201376.\n247 Fadel R, Morrison AR, Vahia A, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis 2020; published online May 19. DOI:10.1093/cid/ciaa601.\n248 Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv 2020; : 2020.06.22.20137273.\n249 UK CMOs and Medical Director of NHS England, Atherton F, Smith G, McBride M. Dexamethasone in COVID-19. 2020; published online June 16.\n[https://www.rpharms.com/Portals/0/RPS%20document%20library/Support%20alert/CMO%20-dexa%20letter.pdf?ver=2020-06-17-092605-187](https://www.rpharms.com/Portals/0/RPS%20document%20library/Support%20alert/CMO%20-dexa%20letter.pdf?)\n(accessed July 5, 2020).\n250 Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1921\u20137.\n251 Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377: 317\u201328.\n252 Xu X, Han M, Li T. Effictive Treatment of Severe COVID-19 Patients with Tocilizumab. 2020. chinaXiv:202003.00026v1 (accessed May 18, 2020).\n253 Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033\u20134.\n254 Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020; published online May 8.\n[DOI:10.1016/S0140-6736(20)31042-4](DOI:10.1016/S0140-6736(20)31042-4)\n.\n255 Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.\n256 Mahevas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv 2020: 2020.04.10.20060699.\n257 Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-10: an open-label, randomized, controlled trial. medRxiv 2020: 2020.04.10.20060558.\n258 Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA 2020; published online May 11.\n[DOI:10.1001/jama.2020.8630](DOI:10.1001/jama.2020.8630)\n.\n259 Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? Clin Infect Dis 2020; 58: 4875.\n260 Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; published online May 22.\n[DOI:10.1016/S0140-6736(20)31180-6](DOI:10.1016/S0140-6736(20)31180-6)\n.\n261 Funck-Brentano C, Salem J-E. Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? Lancet 2020; published online May 22.\n[DOI:10.1016/S0140-6736(20)31174-0](DOI:10.1016/S0140-6736(20)31174-0)\n.\n262 SANOFI, swissmedic. Anwendung von Hydroxychloroquin (Plaquenil, Hydroxychloroquine Zentiva) bei COVID-19 Patienten - Risiko einer QT-Zeit-Verl\u00e4ngerung und Arzneimittelinteraktion. 2020; published online May 27.\n[https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/dhpc_hpc/dhpc hydroxychloroquin.pdf.download.pdf/20200527_DHPC_Hyroxychloroquin_DE.pdf ](https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/dhpc_hpc/dhpc hydroxychloroq)\n(accessed June 6, 2020).\n263 Bonow RO, Hernandez AF, Turakhia M. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. JAMA Cardiol 2020; published online May 1.\n[DOI:10.1001/jamacardio.2020.1782](DOI:10.1001/jamacardio.2020.1782)\n.\n264 Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020; : 2020.03.22.20040758.\n265 Molina JM, Delaugerre C, Le Goff J, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; published online March 30.\n[DOI:10.1016/j.medmal.2020.03.006](DOI:10.1016/j.medmal.2020.03.006)\n.\n266 Cohen MS. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. N Engl J Med 2020; : NEJMe2020388.\n267 Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev 2020; 5: CD013600.\n268 Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117: 9490\u20136.\n269 Liu STH, Lin H-M, Baine I. Convalescehnt plasma treatment of severe COVID-19: A matched control study. 2020; published online May 22.\n[https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1.full.pdf](https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1.full.pdf)\n.\n270 Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med 2020; 382: e38.\n271 Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417\u20138.\n272 Spiezia L, Boscolo A, Poletto F, et al. COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thromb Haemost 2020; 120: 998\u20131000.\n273 Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost 2020; 18: 786\u20137.\n274 Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75: 2950\u201373.\n275 Schweizerische Gesellschaft f\u00fcr H\u00e4matologie. Suggestions for thromboprophylaxis and monitoring for in-hospital patients with COVID-19. 2020; published online April 3.\n[https://www.sgh-ssh.ch/wp-content/uploads/Suggestions-for-thromboprophylaxis-and-monitoring.pdf](https://www.sgh-ssh.ch/wp-content/uploads/Suggestions-for-thromboprophylaxis-and-monitoring.pdf)\n(accessed June 14, 2020).\n276 American Society of Hematology. COVID-19 and Coagulopathy: Frequently asked questions. 2020; published online May 18.\n[https://www.hematology.org/%20covid-19/covid-19-and-coagulopathy](https://www.hematology.org/%20covid-19/covid-19-and-coagulopathy)\n(accessed June 14, 2020).\n277 National Institutes of Health. Antithrombotic Therapy in Patients with COVID-19. 2020; published online May 12.\n[https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/](https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/)\n(accessed July 5, 2020).\n278 Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother 2020; 395: 1054.\n279 British Thoracic Society. British Thoracic Society Guidance on Venous Thromboembolic Disease in patients with COVID-19. 2020; published online May 4.\n[https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/bts-guidance-on-venous-thromboembolic-disease-in-patients-with-covid-19/](https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/bts-guidance-on-venou)\n(accessed June 14, 2020).\n280 Callaway E. The race for coronavirus vaccines. Nature 2020; 580: 576\u20137.\n282 COCONEL Group. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. The Lancet Infectious Diseases 2020; published online May 20.\n[DOI:10.1016/S1473-3099(20)30426-6](DOI:10.1016/S1473-3099(20)30426-6)\n.\n283 Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 Vaccination Program. JAMA 2020; published online May 18.\n[DOI:10.1001/jama.2020.8711](DOI:10.1001/jama.2020.8711)\n.\n284 Tarr PE, Deml MJ, Huber BM. Measles in Switzerland - progress made, but communication challenges lie ahead. Swiss Med Wkly 2019; 149: w20105.\n285 Mello MM, Silverman RD, Omer SB. Ensuring Uptake of Vaccines against SARS-CoV-2. N Engl J Med 2020; : NEJMp2020926.\n286 Forster C. Im Herbst droht eine Grippe- und eine zweite Corona-Welle. Jetzt will der Bund die Zahl der Grippeimpfungen verdoppeln. Neue Z\u00fcrcher Zeitung. 2020; published online June 19.\n287 Gostin LO, Salmon DA. The Dual Epidemics of COVID-19 and Influenza: Vaccine Acceptance, Coverage, and Mandates. JAMA 2020; published online June 11.\n[https://jamanetwork.com/journals/jama/fullarticle/2767284 DOI:10.1001/jama.2020.10802](https://jamanetwork.com/journals/jama/fullarticle/2767284 DOI:10.1001/jama.2020.10802)\n.\n288 Clift, A.K., et al., Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ, 2020. 371: p. m3731.\n289 Knight, S.R., et al., Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ, 2020. 370: p. m3339.\n290 Sperrin, M. and B. McMillan, Prediction models for covid-19 outcomes. BMJ, 2020. 371: p. m3777.\n291 Ioannidis, J.P.A., C. Axfors, and D.G. Contopoulos-Ioannidis, Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res, 2020. 188: p. 109890.\n292 Huizinga, G.P., B.H. Singer, and K. Singer, The Collision of Meta-Inflammation and SARS-CoV-2 Pandemic Infection. Endocrinology, 2020. 161(11).\n293 Popkin, B.M., et al., Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev, 2020. 21(11): p. e13128.\n294 Schultze A., et al., Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med, 2020\n295 SGGG, Expertenbrief SGGG: Coronavirusinfektion, COVID-19, Schwangerschaft und Geburt 2020.\n296 Afshar, Y., et al., Clinical Presentation of Coronavirus Disease 2019 (COVID-19) in Pregnant and Recently Pregnant People. Obstet Gynecol, 2020.\n297 Allotey, J., et al., Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ, 2020. 370: p. m3320.\n298 Knight, M., et al., Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study. BMJ, 2020. 369: p. m2107.\n299 Dallan, C., et al., Septic shock presentation in adolescents with COVID-19. Lancet Child Adolesc Health, 2020. 4(7): p. e21-e23.\n300 Belhadjer, Z., et al., Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation, 2020.\n301 Unit, S.P.S. Swiss Paediatric Surveillance Unit (SPSU). 2020 21.10.2020; Available from:\n[https://www.spsu.ch/en/home](https://www.spsu.ch/en/home)\n.\n302 Del Rio, C., L.F. Collins, and P. Malani, Long-term Health Consequences of COVID-19. JAMA, 2020.\n303 Marshall, M., The lasting misery of coronavirus long-haulers. Nature, 2020. 585(7825): p. 339-341.\n304 Tenforde, M.W., et al., Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep, 2020. 69(30): p. 993-998.\n305 Salisbury, H., Helen Salisbury: When will we be well again? BMJ, 2020. 369: p. m2490.\n306 Petti, S. and B.J. Cowling, Ecologic association between influenza and COVID-19 mortality rates in European countries. Epidemiol Infect, 2020. 148: p. e209.\n307 Comission, E. How many EU citizens die from influenza? 2020 07/04/2020 25.10.2020]; Available from:\n[https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200407-1](https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200407-1)\n.\n308 BAG. COVID-19: Empfehlungen zur Diagnose im ambulanten Bereich. 2020 29.10.2020 30.10.2020]; Available from: https://www.bag.admin.ch/dam/bag/de/dokumente/mt/k-und-i/aktuelle-ausbrueche-pandemien/2019-nCoV/empfehlungen-zur-diagnose-von-covid-19.pdf.download.pdf/Empfehlungen_zur_Diagnose_von_COVID-19.pdf..\n309 Kinder\u00e4rzte Schweiz. Coronavirus - COVID-19. 2020 09.2020 25.10.2020]; Available from:\n[https://www.kinderaerzteschweiz.ch/Fuer-Mitglieder/Coronavirus---COVID-19](https://www.kinderaerzteschweiz.ch/Fuer-Mitglieder/Coronavirus---COVID-19)\n.\n310 Guglielmi, G., Fast coronavirus tests: what they can and can\u2019t do. Nature, 2020. 585(7826): p. 496-498.\n311 Mina, M.J., R. Parker, and D.B. Larremore, Rethinking Covid-19 Test Sensitivity - A Strategy for Containment. N Engl J Med, 2020.\n312 Woloshin, S., N. Patel, and A.S. Kesselheim, False Negative Tests for SARS-CoV-2 Infection - Challenges and Implications. N Engl J Med, 2020. 383(6): p. e38.\n313 Gudbjartsson, D.F., et al., Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med, 2020.\n314 den Hartog, G., et al., SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. J Infect Dis, 2020. 222(9): p. 1452-1461.\n315 Tillett, R.L., et al., Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis, 2020.\n316 Iwasaki, A., What reinfections mean for COVID-19. Lancet Infect Dis, 2020.\n317 van der Made, C.I., et al., Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA, 2020\n318 Hadjadj, J., et al., Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020. 369(6504): p. 718-724.\n319 Pierce, C.A., et al., Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. Sci Transl Med, 2020. 12(564).\n320 Bastard, P., et al., Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020. 370(6515).\n321 Zhang, Q., et al., Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020. 370(6515).\n322 Zietz, M. and N.P. Tatonetti, Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv, 2020.\n323 Latz, C.A., et al., Blood type and outcomes in patients with COVID-19. Ann Hematol, 2020. 99(9): p. 2113-2118.\n324 Sagar, M., et al., Recent endemic coronavirus infection is associated with less severe COVID-19. J Clin Invest, 2020.\n325 Sommerstein, R., et al., Risk of SARS-CoV-2 transmission by aerosols, the rational use of masks, and protection of healthcare workers from COVID-19. Antimicrob Resist Infect Control, 2020. 9(1): p. 100.\n326 Gandhi, M. and G.W. Rutherford, Facial Masking for Covid-19 - Potential for \u00abVariolation\u00bb as We Await a Vaccine. N Engl J Med, 2020.\n327 Beigel, J.H., et al., Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med, 2020.\n328 Pan, H., et al., Repurposed antiviral drugs for COVID-19 \u2013interim WHO SOLIDARITY trial results. medRxiv, 2020: p. 2020.10.15.20209817.\n329 BAG. Koordination der Versorgung mit wichtigen Covid-19-Arzneimitteln. 2020 23.10.2020 25.10.2020]; Available from:\n[https://www.bag.admin.ch/bag/de/home/medizin-und-forschung/heilmittel/covid19_vo_2.html](https://www.bag.admin.ch/bag/de/home/medizin-und-forschung/heilmittel/covid19_vo_2.html)\n.\n330 Tomazini, B.M., et al., Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients. With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA, 2020.\n331 Prescott, H.C. and T.W. Rice, Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA, 2020.\n332 Dequin, P.F., et al., Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA, 2020.\n333 Group, W.H.O.R.E.A.f.C.-T.W., et al., Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA, 2020.\n334 Writing Committee for the, R.-C.A.P.I., et al., Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA, 2020.\n335 Jeronimo, C.M.P., et al., Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin Infect Dis, 2020.\n336 Stone, J.H., et al., Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med, 2020.\n338 Group, R.C., et al., Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med, 2020.\n339 Bloom, B.R., G.J. Nowak, and W. Orenstein, \u201cWhen Will We Have a Vaccine?\u201d - Understanding Questions and Answers about Covid-19 Vaccination. N Engl J Med, 2020.\n340 Schwartz, J.L., Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust. N Engl J Med, 2020.\n341 Rubin, E.J., L.R. Baden, and S. Morrissey, Audio Interview: Vaccinology and Covid-19. N Engl J Med, 2020. 383(16): p. e109.\n342 Green, D.A. and K. StGeorge, Rapid Antigen Tests for Influenza: Rationale and Significance of the FDA Reclassification. J Clin Microbiol, 2018. 56(10).\n343 Leuzinger, K., et al., Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired Respiratory Viruses. J Infect Dis, 2020. 222(8): p. 1270-1279.\n344 Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased Influenza Activity During the COVID-19 Pandemic \u2014 United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1305\u20131309.\n[DOI: http://dx.doi.org/10.15585/mmwr.mm6937a6external icon](DOI: http://dx.doi.org/10.15585/mmwr.mm6937a6external icon)\n345 Dinnes, J., et al., Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev, 2020. 8: p. CD013705\n346 Rhee, C., et al., Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? Clin Infect Dis, 2020.\n347 Grijalva CG, Rolfes MA, Zhu Y, et al. Transmission of SARS-COV-2 Infections in Households \u2014 Tennessee and Wisconsin, April\u2013September 2020. MMWR Morb Mortal Wkly Rep. ePub: 30 October 2020. D\n[OI: http://dx.doi.org/10.15585/mmwr.mm6944e1external icon](OI: http://dx.doi.org/10.15585/mmwr.mm6944e1external icon)\nDie wichtigsten Referenzen\n\u2013 Aktualisierte COVID-19 Therapieempfehlungen der US National Institutes of Health:\n[https://www.COVID19treatmentguidelines.nih.gov/whats-new/](https://www.COVID19treatmentguidelines.nih.gov/whats-new/)\n\u2013 Aktualisierte COVID-19 Therapieempfehlungen des Brigham and Women\u2019s Hospital in Boston:\n[https://covidprotocols.org](https://covidprotocols.org)", "language": null, "image": null, "pagetype": "article", "links": ["https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "#collapseSearch", "/de/article/doi/phc-d.2021.10324/", "/fr/article/doi/phc-f.2021.10324/", "https://www.swisshealthweb.ch/de/newsfeed/", "https://phc.swisshealthweb.ch/de/", "/de/", "/de/aktuelle-ausgabe/", "/de/archiv/", "/de/publizieren/", "/de/ueber-phc/", "https://www.swisshealthweb.ch/de/zeitschriften/", "https://shop.emh.ch/", "https://www.swisshealthweb.ch/de/encyclomed/", "https://events.emh.ch", "https://phc.swisshealthweb.ch/de/article/?tx_cs2services_teaser%5Baction%5D=serviceLinkHandler&tx_cs2services_teaser%5Bcontroller%5D=Services&tx_cs2services_teaser%5Bservice%5D=9&type=96529&cHash=957c22557b087f72957914479c8387b5", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "/de/article/doi/phc-d.2021.10324/", "/fr/article/doi/phc-f.2021.10324/", "https://events.emh.ch/", "https://jobs.saez.ch/de", "https://market.swisshealthweb.ch/de/", "https://shop.emh.ch/", null, "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2021/phc-d.2021.10324/phc-d-2021-10324.pdf", "#otherInfos", "/de/archiv/ausgabe/issue-doi/phc.2021.01/", "https://doi.org/10.4414/phc-d.2021.10324", "javascript:void(0)", "https://phc.swisshealthweb.ch/fileadmin/assets/PHC/2021/phc-d.2021.10324/phc-d-2021-10324.pdf", "https://primary-hospital-care.ch/article/doi/phc-d.2020.10323", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/infektionskrankheiten/grippe/faq-saisonale-grippe.p", "https://www.bag.admin.ch/dam/bag/de/dokumente/mt/i-und-i/grips/executive-summary-erfassung-datenlage", "https://www.infovac.ch/docs/public/influenza/bericht-zur-grippesaison-2018-19-.pdf", "DOI:10.4193/Rhin20.116", "DOI:10.1093/infdis/jiaa161", "https://www.ncbi.nlm.nih.gov/books/NBK554776/", "https://doi.org/10.1371/journal.pmed.1003346", "https://www.bag.admin.ch/bag/de/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-", "http://www.pneumo.ch/files/pneumo/pdf/news/2020/Empfehlungen%20und%20Stellungnahme%20der%20SGP%20DE_", "http://www.swisshypertension.ch/DOCS_PUBLIC/Stellungnahme_COVID_19_D.pdf", "https://www.sgedssed.ch/diabetologie/covid-19", "DOI:10.1002/oby.22831", "DOI:10.1016/S1473-3099(20)30287-5", "DOI:10.1001/jama.2020.10369", "DOI:10.1001/jama.2020.10370", "https://ncs-tf.ch/de/policy-briefs", "https://www.ag.ch/media/kanton_aargau/themen_1/coronavirus_1/merkblaetter/20200505_Grundprinzipien_S", "https://www.drperlmutter.com/wp-content/uploads/2020/05/analysis-of-SARS-CoV-2-viral-load-by-patient", "https://nyti.ms/2SDdFiM", "https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6", "DOI:10.1001/jamacardio.2020.1017", "DOI:10.1001/jamaneurol.2020.1127", "DOI:10.1001/jamaneurol.2020.2065", "DOI:10.1001/jama.2020.6775", "DOI:10.1093/cid/ciaa641", "DOI:10.1093/cid/ciaa674", "https://www.cdc.gov/coronavirus/2019-ncov/community/strategy-discontinue-isolation.html", "DOI:10.1038/s41586-020-2196-x", "DOI:10.1093/cid/ciaa638", "DOI:10.1093/cid/ciaa247", "https://www.iqwig.de/download/RCR_OT_01-_Antibody-tests-for-SARS-CoV-2_23-06-2020.pdf", "https://ncs-tf.ch/de/policy-briefs?layout=default", "https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/5_Forschung_und_Entwicklung/6_Aktuelle_Erreig", "DOI:10.1016/S2468-2667(20)30133-X", "https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-03-16-COVID19-Report-9.pdf", "https://ncs-tf.ch/de/policy-briefs?layout=default", "https://www.sgaim.ch/fileadmin/user_upload/BilderHighres/Seiteninhalte/200423_COVID-19_Schutzkonzept", "https://www.swissnoso.ch/fileadmin/swissnoso/Dokumente/6_Publikationen/Bulletin_Artikel_D/v6_4_1999-", "https://nvs.swiss/Dokumente/Rubrik-Aktuell/2020/Corona-Virus/Schutzmassnahmen-BAG.pdf", "DOI:10.1016/S0140-6736(20)31142-9", "DOI:10.1016/j.jinf.2020.04.024", "https://www.spitexzh.ch/files/G3AVADM/empfehlungen_anwendung_schutzmaterial_2.pdf", "https://www.newsd.admin.ch/newsd/message/attachments/61029.pdf", "https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/diy-cloth-face-coverings.html", "https://ssi.guidelines.ch/guideline/3352", "https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authori", "https://www.nytimes.com/aponline/2020/07/01/world/europe/bc-eu-virus-outbreak-us-hoarding.html", "https://www.rpharms.com/Portals/0/RPS%20document%20library/Support%20alert/CMO%20-dexa%20letter.pdf?", "DOI:10.1016/S0140-6736(20)31042-4", "DOI:10.1001/jama.2020.8630", "DOI:10.1016/S0140-6736(20)31180-6", "DOI:10.1016/S0140-6736(20)31174-0", "https://www.swissmedic.ch/dam/swissmedic/de/dokumente/marktueberwachung/dhpc_hpc/dhpc hydroxychloroq", "DOI:10.1001/jamacardio.2020.1782", "DOI:10.1016/j.medmal.2020.03.006", "https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1.full.pdf", "https://www.sgh-ssh.ch/wp-content/uploads/Suggestions-for-thromboprophylaxis-and-monitoring.pdf", "https://www.hematology.org/%20covid-19/covid-19-and-coagulopathy", "https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/", "https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/bts-guidance-on-venou", "https://www.who.int/docs/default-source/coronaviruse/novel-coronavirus-landscape-covid-19-(1).pdf?sf", "DOI:10.1016/S1473-3099(20)30426-6", "DOI:10.1001/jama.2020.8711", "https://jamanetwork.com/journals/jama/fullarticle/2767284 DOI:10.1001/jama.2020.10802", "https://www.spsu.ch/en/home", "https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200407-1", "https://www.kinderaerzteschweiz.ch/Fuer-Mitglieder/Coronavirus---COVID-19", "https://www.bag.admin.ch/bag/de/home/medizin-und-forschung/heilmittel/covid19_vo_2.html", "https://www.nih.gov/research-training/medical-research-initiatives/activ/covid-19-therapeutics-prior", "DOI:\u00a0http://dx.doi.org/10.15585/mmwr.mm6937a6external icon", "OI:\u00a0http://dx.doi.org/10.15585/mmwr.mm6944e1external icon", "https://www.COVID19treatmentguidelines.nih.gov/whats-new/", "https://covidprotocols.org", "https://emh.ch/en/emh/rights-and-licences/", "#top", null, null, "tel:+410614678555", "#", "https://www.swisshealthweb.ch/de/newsfeed/", "https://www.swisshealthweb.ch/de/informationen-und-services/qualitaetssicherung/", "https://www.swisshealthweb.ch/de/informationen-und-services/publizistische-leitlinien/", "https://www.swisshealthweb.ch/de/informationen-und-services/copyright/", "https://www.swisshealthweb.ch/de/informationen-und-services/newsletter/", "https://www.swisshealthweb.ch/de/verlag/ueber-emh/", "https://www.swisshealthweb.ch/de/verlag/inserieren/", "https://www.swisshealthweb.ch/de/verlag/jobs/", "https://www.swisshealthweb.ch/de/partner/", "https://www.swisshealthweb.ch/de/verlag/hilfe-und-kontakt/", "https://www.swisshealthweb.ch/de/agb/", "https://www.swisshealthweb.ch/de/verlag/impressum/", "https://www.swisshealthweb.ch/de/verlag/datenschutz/", "https://www.swisshealthweb.ch/de/verlag/disclaimer/", "javascript:void()"]}